SAB BIO (Nasdaq: SABS) reported a Q2 2026 net loss of $22.5 million, compared with $10.1 million a year earlier, for the quarter ended June 30, 2026. R&D and G&A expenses both increased as the company expanded the registrational SAFEGUARD trial and added personnel, while $208.0 million of cash, cash equivalents and investment securities provided a stated operating runway through 2028.
Core Financial Results
The wider quarterly loss primarily reflected a $9.2 million increase in R&D expense and a $4.5 million increase in G&A expense. A $1.3 million year-over-year improvement in other income partially offset the higher operating costs but was not enough to prevent the net loss from increasing by $12.4 million.
| Metric (USD millions) | Q2 2026 | Q2 2025 | Year-over-year change |
|---|---|---|---|
| R&D expense | $16.2 | $7.0 | Up $9.2, or approximately 131% |
| G&A expense | $7.2 | $2.7 | Up $4.5, or approximately 167% |
| Other income (expense) | $0.9 income | $0.4 expense | Improved by $1.3 |
| Net loss | $22.5 | $10.1 | Widened by $12.4, or approximately 123% |
| Cash, cash equivalents and investment securities | $208.0 | Not provided | — |
The company attributed the R&D increase mainly to clinical-trial costs and related hiring for SAB-142. Higher headcount and associated stock-based compensation drove the increase in G&A expense.
Pipeline and Operating Progress
SAB BIO had activated more than 60 clinical sites across the United States, Australia, New Zealand, the United Kingdom and the European Union for the Phase 2b SAFEGUARD study. Part A, involving 12 adults, completed enrollment in Q1 2026, while Part B is designed to enroll 147 pediatric, adolescent and adult patients.
Part B enrollment accelerated during Q2 as additional sites opened. The company continues to target full enrollment in Q4 2026, with topline data expected in the second half of 2027. SAFEGUARD is evaluating SAB-142 in Stage 3 type 1 diabetes patients aged 5 to 40 who are within 100 days of diagnosis.
The PRISE-hATG Phase 3 study received grant support from Breakthrough T1D and will also be funded by SAB BIO. The study is designed for 108 participants and could extend SAB-142’s potential future label to Stage 3 type 1 diabetes patients diagnosed up to two years earlier. Its primary objective is to determine whether SAB-142 preserves beta-cell function over 12 months, measured by stimulated C-peptide response.
SAB BIO also began constructing a second farm facility in South Dakota during the quarter. The facility is intended to create a redundant Tc-Bovine herd, increase production capacity and reduce the operational risk associated with relying on a single site.
Profitability and Liquidity
Clinical development remained the main source of expense growth. R&D costs more than doubled as SAFEGUARD advanced, while expansion in staffing also raised administrative costs. The net loss consequently grew at a similar pace, despite higher interest and dividend income from the company’s investment portfolio.
At June 30, SAB BIO held $208.0 million in cash, cash equivalents and investment securities. Management said this capital provides an operating runway through 2028 and is expected to support SAFEGUARD, PRISE-hATG and pre-commercial activities. The release did not provide quarterly operating cash flow or free cash flow figures.
Risks Investors Need to Watch
- SAFEGUARD enrollment timing: Full enrollment remains targeted for Q4 2026. Delays in recruitment could affect the expected timing of topline results in the second half of 2027.
- Clinical outcome risk: The quarter’s update focused on trial execution and did not include new efficacy results. SAB-142’s value remains dependent on future safety and efficacy data.
- Rising development costs: R&D and G&A expenses increased substantially, widening the quarterly net loss. Continued trial expansion and pre-commercial work could keep costs elevated.
- Manufacturing expansion execution: The second farm facility is intended to reduce single-site risk, but construction and establishment of a redundant herd still need to be completed.
Summary
SAB BIO’s Q2 2026 results reflected faster clinical execution alongside a significantly higher cost base. The immediate operating priorities are completing SAFEGUARD enrollment in Q4 2026, advancing the grant-supported PRISE-hATG study and building redundant production capacity, while the $208.0 million liquidity position is intended to fund operations through 2028.
Find out more
Comments